Table 1.
Demographic and clinical characteristics of all patients
| Variable | ALL | Lineage of Mycobacterium tuberculosis isolate | P-value | ||||
|---|---|---|---|---|---|---|---|
| Level | N = 70 (%) | Orphan, n = 12 (%) |
2 (East Asian); n = 25 (%) |
3 (East-African Indian); n = 6 (%) |
4 (Euro-American); n = 27 (%) |
||
| Demographic | |||||||
| Sex | Female | 28 (40%) | 5 (42%) | 5 (20%) | 5 (83%) | 13 (48%) | 0.021 |
| Male | 42 (60%) | 7 (58%) | 20 (80%) | 1 (17%) | 14 (52%) | ||
| Age | Median (range); years | 34 (1–82) | 33.5 (12–61) | 36 (1–60) | 38.5 (32–82) | 33 (9–50) | 0.492 |
| Age groups | Pediatric (<16y) | 5 (7%) | 1 (8%) | 3 (12%) | 0 | 1 (4%) | 0.684 |
| Adult (>16y) | 65 (93%) | 11 (92%) | 22 (88%) | 6 (100%) | 26 (96%) | ||
| TB/DOTS Facilities | Folang | 1 (1%) | 0 | 1 (4%) | 0 | 0 | 0.328 |
| Kalafong | 26 (37%) | 4 (33%) | 8 (32%) | 5 (83%) | 9 (33%) | ||
| Mamelodi | 10 (14%) | 1 (8%) | 2 (8%) | 1 (17%) | 6 (22%) | ||
| Potchefstroom | 4 (6%) | 0 | 0 | 0 | 4 (15%) | ||
| Pretoria West | 4 (6%) | 1 (8%) | 2 (8%) | 0 | 1 (4%) | ||
| Skinner | 2 (3%) | 1 (8%) | 0 | 0 | 1 (4%) | ||
| Steve Biko | 14 (20%) | 3 (33%) | 6 (24%) | 0 | 4 (15%) | ||
| Tshwane | 9 (13%) | 1 (8%) | 6 (24%) | 0 | 2 (7.41% | ||
| Clinical | |||||||
| Disease site | Pleural effusion | 20 (29) | 2 (17) | 4 (16) | 3 (50) | 11 (41) | 0.489 |
| Lymphadenitis | 20 (29) | 4 (33) | 11 (44) | 1 (17) | 4 (15) | ||
| Cutaneous TB | 10 (14) | 3 (25) | 1 (4) | 1 (17) | 5 (19) | ||
| Peritoneal effusion | 5 (7) | 0 | 3 (12) | 0 | 2 (7) | ||
| Meningeal TB | 5 (7) | 1 (8) | 2 (8) | 1 (17) | 1 (4) | ||
| Disseminated | 4 (6) | 1 (8) | 2 (8) | 0 | 1 (4) | ||
| Genitourinary | 2 (3) | 0 | 0 | 0 | 2 (7) | ||
| Other | 4 (6) | 1 (8) | 2 (8) | 0 | 1 (4) | ||
| DR | RIF/INH susceptible | 59 (84) | 9 (75) | 22 (88) | 5 (83) | 23 (85) | 0.125 |
| RIF monoresistant | 6 (9) | 3 (25) | 0 | 0 | 3 (11) | ||
| INH monoresistant | 3 (4) | 0 | 2 (8) | 0 | 1 (4) | ||
| MDR-TB | 2 (3) | 0 | 1 (4) | 1 (17) | 0 | ||
RIF Rifampin; INH Isoniazid; MDR-TB Multidrug resistant tuberculosis; DR Drug resistance